ATE472529T1 - Prolinamidderivate als natriumkanalmodulatoren - Google Patents

Prolinamidderivate als natriumkanalmodulatoren

Info

Publication number
ATE472529T1
ATE472529T1 AT06792409T AT06792409T ATE472529T1 AT E472529 T1 ATE472529 T1 AT E472529T1 AT 06792409 T AT06792409 T AT 06792409T AT 06792409 T AT06792409 T AT 06792409T AT E472529 T1 ATE472529 T1 AT E472529T1
Authority
AT
Austria
Prior art keywords
sodium channel
channel modulators
prolinamide derivatives
prolinamide
derivatives
Prior art date
Application number
AT06792409T
Other languages
German (de)
English (en)
Inventor
Giuseppe Alvaro
Daniele Andreotti
Markus Bergauer
Riccardo Giovannini
Agostino Marasco
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520561A external-priority patent/GB0520561D0/en
Priority claimed from GB0523028A external-priority patent/GB0523028D0/en
Priority claimed from GB0603899A external-priority patent/GB0603899D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE472529T1 publication Critical patent/ATE472529T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06792409T 2005-10-10 2006-10-06 Prolinamidderivate als natriumkanalmodulatoren ATE472529T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0520561A GB0520561D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523028A GB0523028D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603899A GB0603899D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds
PCT/EP2006/009746 WO2007042250A1 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Publications (1)

Publication Number Publication Date
ATE472529T1 true ATE472529T1 (de) 2010-07-15

Family

ID=37546927

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06792409T ATE472529T1 (de) 2005-10-10 2006-10-06 Prolinamidderivate als natriumkanalmodulatoren

Country Status (6)

Country Link
US (1) US7855218B2 (OSRAM)
EP (1) EP1943216B1 (OSRAM)
JP (1) JP5139307B2 (OSRAM)
AT (1) ATE472529T1 (OSRAM)
DE (1) DE602006015215D1 (OSRAM)
WO (1) WO2007042250A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006015215D1 (de) 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
GB0701366D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
JP5121346B2 (ja) * 2007-08-07 2013-01-16 国立大学法人 長崎大学 光学活性プロリンエステル誘導体およびｎ−ホルミル光学活性プロリン誘導体の製造方法
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
JP2013501026A (ja) * 2009-08-05 2013-01-10 クオンベルゲンセ プハルマセウトイカルス リミテッド てんかん及び関連疾患の治療のための共治療法
HRP20150491T1 (hr) 2009-09-14 2015-08-14 Convergence Pharmaceuticals Limited PROCES PRIPREME DERIVATA α-KARBOKSAMIDA
CN102180823B (zh) * 2011-03-12 2016-03-02 浙江华海药业股份有限公司 一种精制脯氨酰胺的方法
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
US9676757B2 (en) 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
US10421716B2 (en) 2014-12-23 2019-09-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
US9624169B2 (en) * 2015-03-27 2017-04-18 Scifluor Life Sciences, Inc. Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds
WO2018213686A1 (en) * 2017-05-19 2018-11-22 Biogen Inc. Novel crystalline forms
KR20200061381A (ko) 2017-10-05 2020-06-02 바이오젠 인크. 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정
AU2018347349A1 (en) 2017-10-10 2020-04-23 Biogen Inc. Process for preparing spiro derivatives
EP4003955A1 (en) 2019-07-30 2022-06-01 Karl-Franzens-Universität Graz Inhibitors of human atgl
CN112679407B (zh) * 2021-03-17 2021-06-04 南京桦冠生物技术有限公司 一种手性5-取代脯氨酸类化合物的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) * 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
KR20020015308A (ko) 1999-03-26 2002-02-27 추후보정 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
CN1805945A (zh) 2003-04-18 2006-07-19 麦克公司 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑
WO2005000309A2 (en) * 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) * 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
EP1877381A1 (en) 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US7858786B2 (en) 2005-05-04 2010-12-28 Vertex Pharmaceuticals Incoropated Pyrimidines and pyrazines useful as modulators of ion channels
WO2006124865A2 (en) 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
MY145713A (en) * 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
DE602006015215D1 (de) 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
JP2009514802A (ja) 2009-04-09
US7855218B2 (en) 2010-12-21
EP1943216A1 (en) 2008-07-16
DE602006015215D1 (de) 2010-08-12
JP5139307B2 (ja) 2013-02-06
US20080306122A1 (en) 2008-12-11
WO2007042250A1 (en) 2007-04-19
EP1943216B1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
ATE433447T1 (de) Pyrimiidinverbindungen
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
NO20082145L (no) Prolinamidderivater som natriumkanalmodulatorer
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200870497A1 (ru) Бензимидазольные модуляторы vr1
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201170772A1 (ru) Органические соединения
MA32508B1 (fr) Composes organiques
EA200970156A1 (ru) Пиридизиноновые производные
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
WO2006086562A3 (en) Phenylazetidinone derivatives
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
BRPI0513310A (pt) análogos de tetrapeptìdeo
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
TW200738659A (en) Novel compounds
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
TW200728258A (en) Novel compounds
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties